Skip to content
Peptide research

Cagrilintide

Also known as NN9838 ยท AM833
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic amylin analog for significant weight loss, studied alone and with semaglutide in the fixed combination CagriSema. Human weight-loss evidence is strong, but claims of gentler GI tolerability than GLP-1 agonists are speculative. Gastrointestinal effects hit 41 to 63 percent of patients, and a theoretical thyroid cancer risk with limited long-term safety data remain unresolved. It is not FDA-approved.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Cagrilintide is a long-acting synthetic version of amylin, a natural hormone your pancreas releases alongside insulin after meals to help regulate appetite and blood sugar. Developed by Novo Nordisk, it is engineered with chemical modifications that extend its activity to about a week, enabling once-weekly dosing. It is being studied primarily for obesity treatment, both alone and in combination with semaglutide (as CagriSema).

How it works in the body

A long-acting analog of amylin, a hormone your pancreas releases after meals. It activates amylin receptors in the brain's appetite centers (area postrema and nucleus tractus solitarius), creating a sense of fullness, slowing stomach emptying, and reducing food intake.

Research overview

Cagrilintide works by binding to amylin receptors in key appetite centers of the brain โ€” particularly the area postrema and hypothalamus โ€” to reduce hunger and food intake through both biological and pleasure-related satiety pathways. It also slows the rate food leaves your stomach (so you feel full longer) and reduces glucagon, a hormone that raises blood sugar. Its mechanism is distinct from GLP-1 drugs like semaglutide. In trials, cagrilintide alone (2.4 mg weekly) produced roughly 9-11% body weight loss over 26-68 weeks โ€” comparable to established GLP-1 drugs โ€” with notably lower rates of vomiting. In the fixed combination with semaglutide (CagriSema), weight loss reached approximately 20-23% at 68 weeks, exceeding semaglutide alone by about 5.5 additional percentage points (Phase 3 REDEFINE 1). Novo Nordisk submitted a New Drug Application to the FDA in December 2025 for CagriSema, with review expected in 2026-2027. Cagrilintide alone does not yet have a separate NDA.

Who researches Cagrilintide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching significant weight loss

    One of the primary studied benefits of Cagrilintide.

Important considerations for

  • Those with Personal/family history of MTC

    Absolute

    Amylin/calcitonin receptor agonist with precautionary MTC contraindication similar to GLP-1 class.

  • Those with History of pancreatitis

    High

    Pancreatitis risk requires monitoring. Patients with prior pancreatitis should discuss risks carefully.

  • Those with Severe gastroparesis

    High

    Amylin analogs slow gastric emptying. Pramlintide (same class) is contraindicated in gastroparesis.

  • Those with Hypoglycemia unawareness

    High

    When co-administered with insulin, amylin analogs significantly increase severe hypoglycemia risk.

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data.

Safety & interactions

Do not use if

  • Personal/family history of MTC

    Absolute

    Personal/family history of MTC โ€” semaglutide is contraindicated; cagrilintide has no approved prescribing label.

  • History of pancreatitis

    High

    Pancreatitis risk requires monitoring. Patients with prior pancreatitis should discuss risks carefully.

  • Severe gastroparesis

    High

    Amylin analogs slow gastric emptying. Pramlintide (same class) is contraindicated in gastroparesis.

  • Hypoglycemia unawareness

    High

    When co-administered with insulin, amylin analogs significantly increase severe hypoglycemia risk.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

How to read the ratings

Benefits
= confidence in the evidence: High ยท Medium ยท Low ยท Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High ยท Moderate ยท Low ยท Theoretical
Interactions
= direction with this peptide: Protective / Synergistic ยท Caution ยท Neutral

Risk summary(11)

Rated by level of concern

  • Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation, abdominal pain) affecting 41-63% of patients at therapeutic doses

    High

    PMID 34798060; PMID 40544433

  • Injection site reactions including redness, swelling, and pain at the subcutaneous injection site

    Moderate

    PMID 34798060

  • The MTC contraindication belongs to semaglutide labeling; it is not an approved cagrilintide-specific contraindication.

    Theoretical

    GLP-1 receptor agonist class boxed warning, semaglutide FDA labeling (accessdata.fda.gov). CagriSema is investigational and not FDA-approved; no cagrilintide monotherapy label exists to carry this contraindication.

  • Semaglutide is contraindicated in MEN2; cagrilintide-specific approved contraindications have not been established.

    Theoretical

    Semaglutide FDA labeling (accessdata.fda.gov), GLP-1 class boxed warning

  • Risk of hypoglycemia when combined with insulin or insulin secretagogues (sulfonylureas)

    Moderate

    SYMLIN (pramlintide) FDA label, accessdata.fda.gov (boxed warning for severe insulin-induced hypoglycemia)

  • May exacerbate symptoms in patients with gastroparesis or delayed gastric emptying

    Moderate

    SYMLIN FDA label (contraindicated in confirmed gastroparesis); PMID 34798060 (trial exclusion criteria)

  • Not evaluated in pregnant or lactating individuals; should be avoided unless clinically justified

    Moderate

    Trial exclusion criteria, cagrilintide phase 2 and REDEFINE phase 3 programs (PMID 34798060; PMID 40544433).

  • Caution required in severe renal impairment (eGFR <30 mL/min/1.73 m2) due to insufficient safety data

    Low

    Trial exclusion criteria (PMID 34798060; PMID 40544433).

  • Long-term safety data beyond 68 weeks is currently limited

    Moderate

    PMID 40544433; PMID 40544432; PMID 34798060

  • Potential interaction with warfarin due to rapid weight loss affecting drug metabolism

    Theoretical

    No primary source; mechanism-only extrapolation from amylin-analog gastric-emptying effects (SYMLIN FDA label)

  • Higher vomiting rates observed with CagriSema combination (OR 9.57) compared to semaglutide alone

    Moderate

    PMID 40544433 (REDEFINE 1). The OR 9.57 and its CI rest on a single source and are unconfirmed.

Interaction summary(8)

Rated by direction with this peptide

  • Insulin

    CautionModerate

    Amylin analogs added to insulin raise hypoglycemia risk - pramlintide carries an FDA boxed warning and requires prandial insulin dose reduction - so insulin doses should be reduced and glucose monitored closely if cagrilintide is started. No cagrilintide-specific insulin interaction study exists; this is class-based inference, which is why severity is Moderate rather than High.

    SYMLIN (pramlintide) FDA label, accessdata.fda.gov (boxed warning)

  • Sulfonylureas and other insulin secretagogues

    CautionModerate

    Weight loss and improved insulin sensitivity on cagrilintide can unmask hypoglycemia from non-glucose-dependent secretagogues, warranting proactive dose review in type 2 diabetes. This is standard practice across the anti-obesity/incretin class rather than a cagrilintide-specific trial finding.

    SYMLIN FDA label (class hypoglycemia precedent); PMID 40544432 (REDEFINE 2, background glucose-lowering therapy managed per protocol)

  • Semaglutide and other GLP-1 receptor agonists

    SynergisticModerate

    The best-evidenced interaction here. Combination gives genuinely additive weight loss (22.7% vs 16.1% for semaglutide alone in REDEFINE 1) but also additive gastrointestinal toxicity, with GI adverse events roughly double placebo rates and vomiting markedly increased. The synergy is efficacy-positive and tolerability-negative. Directly demonstrated in a four-arm phase 3 RCT.

    PMID 40544433 (REDEFINE 1); PMID 40544432 (REDEFINE 2)

  • Oral drugs requiring rapid absorption (analgesics, antibiotics, oral contraceptives)

    CautionLow

    Delayed gastric emptying can slow and blunt oral absorption; pramlintide labeling advises giving such drugs at least 1 hour before or 2 hours after injection. There are no cagrilintide oral-absorption interaction studies at all, and the once-weekly amylin analog's gastric-emptying effect is less characterized than pramlintide's prandial effect. Mechanistically reasonable precaution, entirely untested for cagrilintide.

    SYMLIN FDA label (oral drug timing advice).

  • Anticholinergics and opioid analgesics (gut-motility-slowing agents)

    CautionLow

    Additive slowing of gastric emptying and constipation risk; pramlintide labeling advises against concurrent use of drugs that alter GI motility. The same caution is reasonable here, though untested for cagrilintide.

    SYMLIN FDA label

  • Prokinetics (metoclopramide, erythromycin)

    CautionTheoretical

    Pharmacodynamic opposition - prokinetics counteract the intended gastric-emptying delay - and pramlintide labeling advises against concurrent use. No cagrilintide-specific data exist.

    SYMLIN FDA label

  • Antihypertensives and diuretics

    CautionLow

    Substantial weight loss plus reduced oral intake lowers blood pressure and intravascular volume, so antihypertensive and diuretic doses may need downward adjustment to avoid hypotension or dehydration. This is a consistent observation across the anti-obesity pharmacotherapy class, not a cagrilintide-specific trial finding.

    Anti-obesity pharmacotherapy class experience; PMID 40544433 (blood-pressure reductions observed with weight loss in REDEFINE 1)

  • Alcohol

    CautionLow

    Alcohol compounds hypoglycemia risk in patients also taking insulin or secretagogues and can worsen nausea during dose escalation. This is general diabetes/GI pharmacology advice rather than a documented amylin-analog interaction - a practical caution, not an established interaction.

    General diabetes pharmacotherapy guidance (hypoglycemia risk with alcohol); no cagrilintide- or pramlintide-specific alcohol interaction study.

Known risks(11)

  • Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation, abdominal pain) affecting 41-63% of patients at therapeutic doses

  • Injection site reactions including redness, swelling, and pain at the subcutaneous injection site

  • Semaglutide is contraindicated in patients with a personal or family history of MTC; cagrilintide has no approved prescribing label.

  • MEN2 is a labeled semaglutide contraindication; cagrilintide has no approved prescribing label.

  • Risk of hypoglycemia when combined with insulin or insulin secretagogues (sulfonylureas)

  • May exacerbate symptoms in patients with gastroparesis or delayed gastric emptying

  • Not evaluated in pregnant or lactating individuals; should be avoided unless clinically justified

  • Caution required in severe renal impairment (eGFR <30 mL/min/1.73 m2) due to insufficient safety data

  • Long-term safety data beyond 68 weeks is currently limited

  • Potential interaction with warfarin due to rapid weight loss affecting drug metabolism

  • Higher vomiting rates observed with CagriSema combination (OR 9.57) compared to semaglutide alone

Drug interactions(6)

  • Semaglutide

    CagriSema combines cagrilintide with semaglutide for additive weight loss through complementary amylin and GLP-1 pathways. No pharmacokinetic interference observed. The combination achieves approximately 9% additional weight loss beyond semaglutide alone.

  • Insulin

    Co-administration with insulin increases hypoglycemia risk. Dose reduction of insulin may be necessary when initiating cagrilintide therapy.

  • Sulfonylureas

    Insulin secretagogues combined with cagrilintide may increase hypoglycemia risk. Dose adjustment of the sulfonylurea may be required.

  • Liraglutide

    Both are used for weight management; concurrent use has not been studied and would involve overlapping mechanisms of appetite suppression and GI effects. Not recommended to combine.

  • Pramlintide

    Pramlintide is also an amylin analog; concurrent use would produce overlapping receptor activation with unpredictable dose-response effects and is not recommended.

  • Warfarin

    Rapid weight loss from cagrilintide may alter warfarin metabolism and affect INR levels. Monitoring of coagulation parameters is advised.

Research & benefits

Evidence base

Evidence Level
Strong
Total Studies
8
Human Participants
3000

Cagrilintide has been evaluated in multiple Phase 1, Phase 2, and Phase 3 randomized controlled trials. The Phase 2 dose-finding trial (n=706) demonstrated dose-dependent weight loss up to 10.8% with the 4.5 mg dose. A Phase 1b trial (n=96) confirmed acceptable safety when co-administered with semaglutide 2.4 mg, with no pharmacokinetic interference. A Phase 2 trial in type 2 diabetes (n=92) showed CagriSema achieved 15.6% weight loss and 2.2% HbA1c reduction. The REDEFINE Phase 3 program demonstrated approximately 20-23% weight loss with CagriSema vs placebo. A systematic review and meta-analysis of 3 RCTs (n=430) confirmed CagriSema provides 9% additional weight loss over semaglutide alone with an acceptable safety profile. Evidence quality is rated strong based on multiple well-designed RCTs, though longer-term safety data beyond 68 weeks is still needed.

Researched for(6)

Rated by confidence in the evidence

  • Significant Weight Loss

    High

    The phase 2 trial showed 6.0โ€“10.8% weight loss from baseline versus 3.0% with placebo; the highest cagrilintide dose outperformed liraglutide.

    PMID 34798060 (Lancet 2021;398:2160-72, cagrilintide phase 2 dose-finding); PMID 40544433 (NEJM 2025, REDEFINE 1)

  • Appetite and Satiety Regulation

    Medium

    Appetite suppression is mechanism based, inferred from weight loss trials rather than directly measured in humans.

    PMID 34798060 (weight-loss dose-response, appetite inferred); SYMLIN (pramlintide) FDA label for class satiety/energy-intake effects

  • Improved GI Tolerability vs GLP-1 Agonists

    Low

    REDEFINE 1 directly randomized participants to cagrilintide, semaglutide, their combination, or placebo.

    PMID 34798060 (phase 2, includes liraglutide 3.0 mg active comparator). The vomiting-specific advantage rests solely on an Indian J Endocrinol Metab 2024 meta-analysis; the OR 0.38 figure is unconfirmed.

  • Complementary Mechanism for Combination Therapy

    High

    Phase 3 trials show the combination produces greater weight loss than either drug alone.

    PMID 40544433 (REDEFINE 1, NEJM 2025); PMID 40544432 (REDEFINE 2, NEJM 2025)

  • Metabolic Improvements

    Medium

    Metabolic benefits are shown mainly for the combination product, less established for cagrilintide alone.

    PMID 40544432 (REDEFINE 2); PMID 34798060

  • Convenient Once-Weekly Dosing

    Medium

    Once weekly dosing is pharmacokinetically established, though the adherence benefit itself was never directly tested.

    PMID 34798060; PMID 40544433 (both used once-weekly dosing; neither measured adherence or convenience)

Benefits(6)

  • Significant Weight Loss

  • Appetite and Satiety Regulation

  • Improved GI Tolerability vs GLP-1 Agonists

  • Complementary Mechanism for Combination Therapy

  • Metabolic Improvements

  • Convenient Once-Weekly Dosing

Key studies(5)

  1. Lau DCW, Erichsen L, Francisco-Ziller N, et al.

    The Lancet

    2021

    Cagrilintide at doses of 0.3-4.5 mg weekly produced dose-dependent weight loss of 6.0-10.8% over 26 weeks, with the highest dose significantly outperforming liraglutide 3.0 mg (p=0.03). Gastrointestinal adverse events were most common but generally mild to moderate.

  2. Enebo LB, Berthelsen KK, Kankam M, et al.

    The Lancet

    2021

    Co-administration of cagrilintide (0.16-4.5 mg) with semaglutide 2.4 mg was well tolerated with no pharmacokinetic interference. The combination achieved up to 17.1% weight loss at 20 weeks. Cagrilintide half-life was 159-195 hours, supporting once-weekly dosing.

  3. Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, et al.

    The Lancet

    2023

    CagriSema achieved 15.6% weight loss and 2.2 percentage point HbA1c reduction at 32 weeks in type 2 diabetes patients, significantly exceeding both semaglutide alone (5.1% weight loss) and cagrilintide alone (8.1% weight loss).

  4. D'Ascanio AM, Mullally JA, Frishman WH

    Cardiology in Review

    2024

    Comprehensive review confirming cagrilintide's dual mechanism via amylin and calcitonin receptors. Both monotherapy and combination with semaglutide showed promising weight loss in clinical trials, with the combination approaching additive effects through complementary pathophysiological targets.

  5. Dutta D, et al.

    Indian Journal of Endocrinology and Metabolism

    2024

    Meta-analysis of 3 RCTs (n=430) confirmed CagriSema provides 9.07% additional weight loss over semaglutide alone (p<0.00001). Cagrilintide monotherapy showed comparable efficacy to GLP-1 agonists with significantly lower vomiting rates (OR 0.38, p=0.02).

What research suggests over time

  • Weeks 2-4

    Phase 2 (Lancet 2021)

    Appetite reduction via amylin/calcitonin receptor pathway begins during dose titration.

  • Months 2-3

    Phase 2 RCT

    Dose-dependent weight loss of 6.0-10.8% over 26 weeks (monotherapy).

  • Long-term

    Phase 2 (CagriSema)

    CagriSema (cagrilintide with semaglutide) achieved 15.6% weight loss and a 2.2 percentage point HbA1c reduction at 32 weeks in T2DM. Novo Nordisk filed an NDA in December 2025.

Regulation & availability

Why researchers look at it

On its own, cagrilintide produced 9-11% body weight loss over 26-68 weeks in trials, with notably lower vomiting than GLP-1 agonists, by activating amylin signaling, a fundamentally different appetite pathway. In the fixed combination with semaglutide (CagriSema), it produced approximately 20-23% weight loss at 68 weeks, exceeding semaglutide alone by about 5.5 additional percentage points (Phase 3 REDEFINE 1). Novo Nordisk submitted an NDA in December 2025, with an FDA decision expected late 2026 to early 2027.

Estimated cost
Not yet available โ€” NDA submitted to FDA (Novo Nordisk)
FDA status
Not FDA-approved as of March 2026. Novo Nordisk submitted a New Drug Application (NDA) to the FDA on December 18, 2025, for CagriSema (cagrilintide with semaglutide) for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The FDA is expected to complete its standard review (10-12 months) in late 2026 to early 2027, though priority review could accelerate this to late 2026. Cagrilintide as a standalone agent has not been submitted for FDA approval separately. The FDA has explicitly stated that cagrilintide has not been found safe and effective for any condition and cannot be used in compounding.
WADA status
Prohibited at all times under the 2026 WADA S0 rule for unapproved pharmacological substances. Cagrilintide is not named individually; its investigational status brings it within S0.
Prescribability
Investigational
Availability
Not commercially available. Cagrilintide is currently accessible only through participation in Novo Nordisk clinical trials (REDEFINE program). CagriSema (the fixed combination of cagrilintide and semaglutide) has been submitted to the FDA for review as of December 2025. It is not available through compounding pharmacies, as the FDA has stated it cannot be used in compounding under federal law.

International status

  • EU

    Regulatory submission expected

  • US

    NDA submitted (Novo Nordisk)

  • Worldwide

    Investigational

Regulatory timeline(7)

  1. 2018
    Phase 1 trials initiatedA phase 1b trial of cagrilintide combined with semaglutide was underway, with participant screening beginning July 25, 2018.
  2. 2021
    Phase 1b results publishedEnebo et al. published results in The Lancet showing acceptable safety and up to 17.1% weight loss when co-administered with semaglutide 2.4 mg over 20 weeks.
  3. 2021
    Phase 2 dose-finding results publishedLau et al. published results in The Lancet showing dose-dependent weight loss of 6.0-10.8% with cagrilintide monotherapy over 26 weeks in 706 participants.
  4. 2023
    Phase 2 type 2 diabetes results publishedFrias et al. published in The Lancet showing CagriSema achieved 15.6% weight loss and 2.2% HbA1c reduction in type 2 diabetes patients over 32 weeks.
  5. 2025
    REDEFINE Phase 3 program resultsREDEFINE 1 and REDEFINE 2 results were published in the New England Journal of Medicine. At 68 weeks, the treatment-policy estimates for CagriSema weight loss were 20.4% without diabetes and 13.7% with type 2 diabetes, respectively. The approximately 23% figure comes from REDEFINE 1's treatment-adherent analysis.
  6. 2025-12
    NDA submitted to FDANovo Nordisk submitted a New Drug Application to the FDA on December 18, 2025, for once-weekly CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) for chronic weight management.
  7. 2026-2027
    FDA review expectedStandard FDA review (10-12 months) would result in a decision in late 2026 to early 2027. Priority review, if granted, could yield a decision in late 2026.

Sources & FAQs

Research sources(8)

Frequently asked questions(5)

What is the difference between cagrilintide and semaglutide?

Cagrilintide is an amylin analog that works by activating amylin and calcitonin receptors in the brain to reduce appetite and slow gastric emptying. Semaglutide is a GLP-1 receptor agonist that works through a different pathway to suppress appetite and enhance insulin secretion. They target distinct but complementary mechanisms, which is why their combination (CagriSema) produces significantly greater weight loss than either drug alone.

When will cagrilintide be available by prescription?

Novo Nordisk submitted CagriSema (cagrilintide + semaglutide) for FDA approval in December 2025. If the standard review timeline is followed, approval could come in late 2026 or early 2027. Cagrilintide as a standalone drug has not been submitted for separate approval. Currently, access is limited to clinical trials.

How much weight can you lose with cagrilintide?

In clinical trials, weekly cagrilintide monotherapy produced approximately 9-11% body weight loss over 26-68 weeks. The combination with semaglutide (CagriSema) achieved approximately 20-23% weight loss at 68 weeks in Phase 3 trials, which represents some of the highest weight loss seen with any pharmacological intervention.

What are the main side effects of cagrilintide?

The most common side effects are gastrointestinal symptoms including nausea (20-47% of patients), constipation, diarrhea, and injection site reactions. These are generally mild to moderate and often transient. Notably, cagrilintide monotherapy has significantly lower vomiting rates compared to GLP-1 agonists. In the phase 2 trial, 10% permanently discontinued treatment overall; 4% discontinued because of adverse events.

Can cagrilintide be used for type 2 diabetes?

While cagrilintide was primarily developed for obesity treatment, Phase 2 trials in type 2 diabetes patients showed that CagriSema reduced HbA1c by 2.2 percentage points and fasting plasma glucose significantly. However, cagrilintide alone had more modest glycemic effects compared to semaglutide. The drug is being primarily developed for weight management rather than glycemic control.